![]() At this point, the company has supplied the US government with 18 million doses and projects to make nearly 100 million doses available to Americans by the end of the first quarter of 2021. The company announces it will increase production from 500 million doses to 600 million doses for 2021 and plans to allocate resources to produce 1 billion doses in total this year. Moderna to Produce 600 Million Vaccine Doses ![]() ![]() The agency notes that potential changes would be premature and there is not enough evidence of their efficacy compared with approved 2-dose vaccine schedules. As a result of a highly transmissible variant of COVID-19 spreading throughout the United Kingdom, Prime Minister Boris Johnson hints at upcoming tighter restrictions.įDA Advises Against Altering Vaccine SchedulesįDA issues a statement cautioning health care workers against making changes to authorized dosing schedules for approved COVID-19 vaccines. The United Kingdom begins to inoculate its population with the COVID-19 vaccine manufactured by Oxford University and AstraZeneca, which can be stored at refrigerator temperatures between 2° and 8° Celsius, potentially enabling easier distribution. UK Begins Distributing AstraZeneca/Oxford Vaccine The announcement comes after data show that two 50-mcg doses of Moderna’s vaccine in individuals aged 18 to 55 years resulted in identical immune responses compared with the standard two 100-mcg doses. Operation Warp Speed official Moncef Slaoui, MD, begins discussions with Moderna and the FDA regarding the possibility of half-dose vaccine regimens so as to double the number of people vaccinated against COVID-19. Operation Warp Speed Initiates Talks With Moderna on Half-Dose Vaccines Here is a look at how vaccine development, approval, and rollout has progressed so far in 2021. And with close to 10% of the US population fully vaccinated, updated guidance is starting to roll out. Alaska, New Mexico, North Dakota, South Dakota, and Connecticut have administered the most doses per 100,000 of the total population. As of March 10, the CDC was reporting that more than 93.6 million vaccine doses had been administered. With research into hundreds of vaccine candidates, there are now 3 vaccines approved by the FDA. If 2020 was dominated by the news of how COVID-19 spread across the globe, putting normal life on hold for most people and overwhelming health care providers, then 2021 has so far been focused on ending the pandemic through vaccine distribution. For a full look at how the pandemic evolved throughout 2020, see our timeline from last year. March 11 represents the one-year anniversary since the World Health Organization declared COVID-19 a global pandemic, and shortly after, former President Donald Trump had declared a national emergency, with states beginning to issue stay-at-home orders, mask mandates, and capacity limits at businesses like restaurants and bars. The Agency provides guidance and advice on the evidence required to support and expedite applications to add new sites or increase the capacity of existing sites for the manufacture of high-quality COVID-19 vaccines.Note: This timeline will update throughout the year as new developments take place. These recommendations do not require a European Commission decision and the changes can become operational immediately.ĮMA is in continuous dialogue with all marketing authorisation holders of COVID-19 vaccines as they seek to expand their production capacity for the supply of vaccines. ![]() This increase in production capacity is expected to support the continued supply of Comirnaty in the European Union. Scale-up process for Comirnaty from BioNTech/PfizerĪn increase in production of the active substance of Comirnaty, the COVID-19 vaccine from BioNTech/Pfizer, at the manufacturing site operated by Wyeth BioPharma Division of Wyeth Pharmaceuticals, located in Andover, MA, USA, was also approved by the Committee. These changes will allow the production of around 25 million additional doses of Spikevax every month to the European Union and to third countries through the COVID-19 Vaccines Global Access (COVAX) initiative. The increase in production includes a 50% scale-up of the batch size of the finished product and a second fill-and-finish line. The CHMP has also given a positive opinion for an increase in production of Spikevax, the COVID-19 vaccine from Moderna, at the manufacturing site operated by ROVI Contract Manufacturing, located in Madrid, Spain. Scale-up process for Spikevax from Moderna The site is expected to support the continued supply of COVID-19 Vaccine Janssen. The site, located in Marcy-l'Étoile, France, and operated by Sanofi Pasteur, will manufacture finished product. EMA’s human medicines committee ( CHMP) has approved an additional manufacturing site for the production of COVID-19 Vaccine Janssen, developed by Janssen-Cilag International NV.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |